Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies

Patients with relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma (B-NHL) or acute lymphoblastic leukemia have a poor prognosis. Despite measurable clinical activity with new targeted therapies, many patients do not achieve a complete or durable response suggesting an opportunity to...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Ryan, Maureen C., Palanca-Wessels, Maria Corinna, Schimpf, Brian, Gordon, Kristine A., Kostner, Heather, Meyer, Brad, Yu, Changpu, Van Epps, Heather A., Benjamin, Dennis
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2017
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669207/
https://ncbi.nlm.nih.gov/pubmed/28903943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-779389
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires